Boston Scientific Corporation $BSX Shares Purchased by Generali Investments Towarzystwo Funduszy Inwestycyjnych

Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 72.7% in the 1st quarter, HoldingsChannel reports. The fund owned 38,000 shares of the medical equipment provider’s stock after acquiring an additional 16,000 shares during the quarter. Boston Scientific comprises about 1.2% of Generali Investments Towarzystwo Funduszy Inwestycyjnych’s investment portfolio, making the stock its 22nd biggest holding. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Boston Scientific were worth $2,384,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter valued at about $26,000. Main Street Financial Solutions LLC increased its holdings in Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC lifted its position in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC lifted its position in shares of Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific’s growth prospects, pointing to upcoming catalysts like pulse field ablation (PFA) and Watchman, and TD Cowen reiterated a Buy rating with a lowered price target that still implies meaningful upside. TD Cowen Maintains a Buy Rating on Boston Scientific (BSX)
• Positive Sentiment: Unusually heavy call option buying suggests traders are positioning for a rebound in BSX, which can reflect bullish near-term sentiment.
• Positive Sentiment: Short interest fell sharply in June, dropping 48.3% to about 29.8 million shares, which may indicate easing bearish conviction and could reduce downside pressure.
• Positive Sentiment: One commentary piece argued that Boston Scientific’s pullback may be creating a value opportunity, reinforcing the view that some investors see the stock as oversold. Boston Scientific’s Fall From Penthouse To Doghouse Creates A Value Opportunity
• Neutral Sentiment: A recent note said BSX has been a laggard this year, and although analysts see upside from current levels, the stock is still working to recover from a sharp decline.
• Negative Sentiment: Boston Scientific recently disclosed a nationwide recall of Orca valves after a device malfunction, adding regulatory and operational concerns that may weigh on sentiment. Boston Scientific (BSX) Recalls Orca Valves Nationwide After Device Malfunction
• Negative Sentiment: Investors also remain focused on questions around Watchman and the impact of the device recall, which have changed the investment story and may be contributing to recent stock weakness. How a Targeted Valve Recall and Watchman Questions at Boston Scientific (BSX) Have Changed Its Investment Story

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig bought 3,580 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BSX shares. Jefferies Financial Group lowered their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday. UBS Group reduced their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Needham & Company LLC reissued a “buy” rating and issued a $77.00 target price on shares of Boston Scientific in a report on Monday, May 18th. Canaccord Genuity Group dropped their price target on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Finally, Oppenheimer set a $90.00 price target on Boston Scientific in a research note on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $83.36.

Boston Scientific Trading Down 0.6%

Shares of Boston Scientific stock opened at $44.20 on Friday. Boston Scientific Corporation has a 1 year low of $43.89 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The business has a 50 day moving average price of $53.28 and a 200 day moving average price of $71.32. The company has a market capitalization of $65.70 billion, a P/E ratio of 18.50, a P/E/G ratio of 0.85 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.